Literature DB >> 32450444

Associations between cerebrospinal fluid total phosphatidylcholines, neurodegeneration, cognitive decline, and risk of mild cognitive impairment in the Mayo Clinic Study of Aging.

Danni Li1, Clinton Hagen2, Hai H Bui3, David Knopman4, Clifford R Jack5, Mary Machulda6, Ronald C Petersen7, Michelle M Mielke8.   

Abstract

It is unclear whether cerebrospinal fluid (CSF) phosphatidylcholines (PCs) are associated with neuroimaging measures of amyloid deposition and neurodegeneration (glucose metabolism, cortical thickness, and hippocampal volume), cognitive decline, or risk of mild cognitive impairment (MCI) among cognitively unimpaired older adults. This study investigated the associations of 19 individual CSF PC concentrations and their total sum with cross-sectional and longitudinal measures of amyloid deposition and neurodegeneration, global and domain-specific cognitive z-scores, and risk of MCI among 655 cognitively unimpaired participants, mean age of 71 years, enrolled in the Mayo Clinic Study of Aging. Neither the CSF total PC concentration nor individual CSF PCs were cross-sectionally or longitudinally associated with neuroimaging measures, cognition, or risk of MCI.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cerebrospinal fluid; Cognition; Mild cognitive impairment; Phosphatidylcholines

Mesh：

Substances：

Year:  2020        PMID： 32450444      PMCID： PMC7302967          DOI： 10.1016/j.neurobiolaging.2020.04.020

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


  10 in total

1.  Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients.

Authors:  Anna Walter; Ulrike Korth; Michael Hilgert; Joachim Hartmann; Oksana Weichel; Marion Hilgert; Klaus Fassbender; Andrea Schmitt; Jochen Klein
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

2.  Plasma phospholipids identify antecedent memory impairment in older adults.

Authors:  Mark Mapstone; Amrita K Cheema; Massimo S Fiandaca; Xiaogang Zhong; Timothy R Mhyre; Linda H MacArthur; William J Hall; Susan G Fisher; Derick R Peterson; James M Haley; Michael D Nazar; Steven A Rich; Dan J Berlau; Carrie B Peltz; Ming T Tan; Claudia H Kawas; Howard J Federoff
Journal:  Nat Med       Date:  2014-03-09       Impact factor: 53.440

3.  Longitudinal association between phosphatidylcholines, neuroimaging measures of Alzheimer's disease pathophysiology, and cognition in the Mayo Clinic Study of Aging.

Authors:  Danni Li; Clinton Hagen; Ashely R Fett; Hai H Bui; David Knopman; Prashanthi Vemuri; Mary M Machulda; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Neurobiol Aging       Date:  2019-03-18       Impact factor: 4.673

4.  Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease.

Authors:  M Kosicek; H Zetterberg; N Andreasen; J Peter-Katalinic; S Hecimovic
Journal:  Neurosci Lett       Date:  2012-04-12       Impact factor: 3.046

5.  Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4.

Authors:  M Mulder; R Ravid; D F Swaab; E R de Kloet; E D Haasdijk; J Julk; J J van der Boom; L M Havekes
Journal:  Alzheimer Dis Assoc Disord       Date:  1998-09       Impact factor: 2.703

6.  The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.

Authors:  Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca
Journal:  Neuroepidemiology       Date:  2008-02-07       Impact factor: 3.282

7.  Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels.

Authors:  Therese Koal; Kristaps Klavins; Daniele Seppi; Georg Kemmler; Christian Humpel
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS).

Authors:  Danni Li; Jeffrey R Misialek; Eric Boerwinkle; Rebecca F Gottesman; A Richey Sharrett; Thomas H Mosley; Josef Coresh; Lisa M Wruck; David S Knopman; Alvaro Alonso
Journal:  Alzheimers Dement (Amst)       Date:  2016-05-06

9.  Prospective associations of plasma phospholipids and mild cognitive impairment/dementia among African Americans in the ARIC Neurocognitive Study.

Authors:  Danni Li; Jeffrey R Misialek; Eric Boerwinkle; Rebecca F Gottesman; A Richey Sharrett; Thomas H Mosley; Josef Coresh; Lisa M Wruck; David S Knopman; Alvaro Alonso
Journal:  Alzheimers Dement (Amst)       Date:  2016-11-01

10.  Particular CSF sphingolipid patterns identify iNPH and AD patients.

Authors:  Enrica Torretta; Beatrice Arosio; Pietro Barbacini; Martina Casati; Daniele Capitanio; Roberta Mancuso; Daniela Mari; Matteo Cesari; Mario Clerici; Cecilia Gelfi
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379
  10 in total
  1 in total

1.  Neurobiological effects of phospholipids in vitro: Relevance to stress-related disorders.

Authors:  Francisco Donoso; Marina Schverer; Kieran Rea; Matteo M Pusceddu; Bernard L Roy; Timothy G Dinan; John F Cryan; Harriët Schellekens
Journal:  Neurobiol Stress       Date:  2020-09-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.